Preliminary report: Treatment of the hemolytic-uremic syndrome with aspirin and dipyridamole

Paul S. Lietman, Edward B. Arenson, Charles S. August

Research output: Contribution to journalArticlepeer-review

Abstract

Three children with the hemolytic-uremic syndrome were treated with heparin, aspirin, and dipyridamole. Twoof the children had remained profoundly thrombocytopenic in spite of platelet transfusions and heparin therapy. All three patients responded with prompt elevation of their platelet counts and apparent termination of the pathologic consumption of platelets. Our experience suggests not only that primary platelet consumption may play a critical role in the pathogenesis of the HUS, but also that such patients may benefit from therapy with drugs which inhibit platelet function.

Original languageEnglish (US)
Pages (from-to)957-961
Number of pages5
JournalThe Journal of pediatrics
Volume86
Issue number6
DOIs
StatePublished - Jun 1975

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Preliminary report: Treatment of the hemolytic-uremic syndrome with aspirin and dipyridamole'. Together they form a unique fingerprint.

Cite this